KR102494174B1 - 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합 - Google Patents

정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합 Download PDF

Info

Publication number
KR102494174B1
KR102494174B1 KR1020187033052A KR20187033052A KR102494174B1 KR 102494174 B1 KR102494174 B1 KR 102494174B1 KR 1020187033052 A KR1020187033052 A KR 1020187033052A KR 20187033052 A KR20187033052 A KR 20187033052A KR 102494174 B1 KR102494174 B1 KR 102494174B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
cells
compound
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187033052A
Other languages
English (en)
Korean (ko)
Other versions
KR20180132882A (ko
Inventor
마리아 빌렌칙
마이클 프라이드
알렉산드라 쿠즈넷소바
유리이 간킨
마크 듀이
Original Assignee
펠리시텍스 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펠리시텍스 쎄라퓨틱스, 인코포레이티드 filed Critical 펠리시텍스 쎄라퓨틱스, 인코포레이티드
Priority to KR1020237002826A priority Critical patent/KR20230020565A/ko
Publication of KR20180132882A publication Critical patent/KR20180132882A/ko
Application granted granted Critical
Publication of KR102494174B1 publication Critical patent/KR102494174B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187033052A 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합 Active KR102494174B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237002826A KR20230020565A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
US62/323,537 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002826A Division KR20230020565A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합

Publications (2)

Publication Number Publication Date
KR20180132882A KR20180132882A (ko) 2018-12-12
KR102494174B1 true KR102494174B1 (ko) 2023-02-02

Family

ID=60039950

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187033052A Active KR102494174B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
KR1020237002826A Ceased KR20230020565A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237002826A Ceased KR20230020565A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합

Country Status (11)

Country Link
US (3) US10322128B2 (https=)
EP (1) EP3442505A4 (https=)
JP (2) JP7123806B2 (https=)
KR (2) KR102494174B1 (https=)
CN (1) CN109562176A (https=)
AU (2) AU2017248762A1 (https=)
BR (1) BR112018071031A2 (https=)
CA (1) CA3021021A1 (https=)
IL (2) IL262323B (https=)
MX (2) MX2018012511A (https=)
WO (1) WO2017181075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400003B1 (en) * 2016-01-05 2023-05-03 The Trustees of Columbia University in the City of New York Compositions for regulating activity of inhibitor of dna binding-2 (id2) protein
EP3443351A4 (en) 2016-04-15 2019-12-18 Felicitex Therapeutics, Inc. COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS
CA3021021A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
WO2020235973A1 (ko) * 2019-05-22 2020-11-26 주식회사 보로노이 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CN117479943A (zh) * 2021-06-15 2024-01-30 基因泰克公司 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
ES2917526T3 (es) * 2015-07-23 2022-07-08 Calgent Biotechnology Co Ltd Compuestos de aminonaptoquinona y composición farmacéutica para bloquear el sistema ubiquitinación-proteasoma en enfermedades
EP3443351A4 (en) 2016-04-15 2019-12-18 Felicitex Therapeutics, Inc. COMBINATIONS FOR THE TREATMENT OF NEOPLASIA BY TARGETING RESTING CELLS AND INHIBITORS OF MITOSIS
CA3021021A1 (en) 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) * 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells

Also Published As

Publication number Publication date
MX2018012511A (es) 2019-07-08
CN109562176A (zh) 2019-04-02
IL262323B (en) 2022-03-01
EP3442505A4 (en) 2019-12-18
US20190298723A1 (en) 2019-10-03
KR20230020565A (ko) 2023-02-10
AU2023200428A1 (en) 2023-03-02
WO2017181075A1 (en) 2017-10-19
US20220110940A1 (en) 2022-04-14
EP3442505A1 (en) 2019-02-20
AU2017248762A1 (en) 2018-11-01
JP7123806B2 (ja) 2022-08-23
MX2023000549A (es) 2023-02-13
KR20180132882A (ko) 2018-12-12
JP2022145800A (ja) 2022-10-04
US10322128B2 (en) 2019-06-18
US20170296541A1 (en) 2017-10-19
CA3021021A1 (en) 2017-10-19
BR112018071031A2 (pt) 2019-02-12
JP2019511554A (ja) 2019-04-25
US11202779B2 (en) 2021-12-21
IL288777A (en) 2022-02-01
IL262323A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
KR102494174B1 (ko) 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
KR102494172B1 (ko) 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
JP6637884B2 (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
US8138356B2 (en) Chemical inhibitors of inhibitors of differentiation
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
AU2021348477B2 (en) Csf1r kinase inhibitor and use thereof
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
JP2018535996A (ja) 血液癌を処置するためのセルデュラチニブ
JP2020169222A (ja) 癌を治療するための方法
KR20210091758A (ko) Mcl-1 억제제와 미도스타우린의 조합물, 이의 용도 및 약학적 조성물
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
HK40059071A (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601